Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Simple ultrasound check may replace complex stroke risk test

NCT ID NCT05780619

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tests whether a quick, routine ultrasound measurement (called the resistance index) can accurately identify people with narrowed neck arteries who have normal brain blood flow response. If it works, many patients could avoid a time-consuming, specialized test. The study will involve 77 participants with significant carotid artery narrowing or blockage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a quick, simple test to identify which patients with carotid artery narrowing need further evaluation for stroke risk.
What could go wrong
This is a small, early-stage diagnostic study (77 participants) testing a new use for an existing measure. The results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 77 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will be carried out at the University Hospital of Nîmes in the department of explorations and vascular medicine (EMV), for patients referred for HRV measurement with a significant stenosis or occlusion.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * Stenosis ≥ 70% in diameter reduction in NASCET equivalent or occlusion of atheromatous origin of the cervical internal carotid artery, asymptomatic or symptomatic. * Presence of a temporal window sufficient to record the homolateral and contralateral middle cerebral artery. * Patient of legal age with free and informed consent. * Patient who has signed the consent form. * Patient affiliated or beneficiary of a health insurance plan. Exclusion Criteria: * The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Contraindication to Acetazolamide Diamox® injection. * Absence of temporal acoustic window (non visualization of the cerebral parenchyma, no recordable intracranial vessel). * Insufficient temporal window (visualizable brain parenchyma, no recordable MCA) * Internal or common carotid artery stenosis ≥70% or occlusion, contralateral to the primary lesion. * Stenosis ≥50% of the middle cerebral artery homolateral or contralateral to the cervical lesion. * Patient in exclusion period determined by another study. * Patient under court protection, guardianship, or conservatorship. * Patient refusing to sign the consent form. * Patient unable to express his or her will (dementia, disturbed consciousness, etc.) * Patient for whom it is impossible to give informed information for health reasons or because of a language barrier. * Pregnant, parturient, or breastfeeding patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carotid artery occlusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nîmes

    RECRUITING

    Nîmes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.